Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16128003 | 0.88 | KMT2A (0.47) | PPARGAKR1C3CARM1PRMT6LOXL2 | |
| SCHEMBL17570344 | 0.87 | CARM1 (0.49) | PPARGAKR1C3CARM1PRMT6LOXL2 | |
| SCHEMBL16128005 | 0.86 | KMT2A (0.50) | CARM1PRMT6KMT2AMEN1TDP1 | |
| SCHEMBL17570355 | 0.82 | SLC6A4 (0.46) | CARM1PRMT6 | |
| SCHEMBL16128023 | 0.81 | TTR (0.52) | CARM1PRMT6 | |
| SCHEMBL16128004 | 0.75 | KMT2A (0.49) | CARM1PRMT6KMT2AMEN1NPC1 | |
| SCHEMBL7307728 | 0.74 | MAPK8 (0.78) | LOXL2KMT2A | |
| SCHEMBL7312518 | 0.74 | RAB9A (0.59) | PPARGAKR1C3LOXL2RAB9ATDP1 | |
| SCHEMBL5878723 | 0.74 | HTR2A (0.63) | — | |
| SCHEMBL16128001 | 0.74 | KMT2A (0.48) | CARM1PRMT6KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
| WO-2014152536-A2 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | PPARG 1869/4885AKR1C3 625/4885CARM1 4718/4885 |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | PPARG 1869/4885AKR1C3 625/4885CARM1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.